Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company pioneering Precision Timed Release™ (PTR™) technology to develop advanced treatments for ADHD and anxiety disorders. This page serves as the definitive source for verified company updates, offering investors and healthcare professionals timely access to essential developments.
Find comprehensive coverage of clinical trial milestones, regulatory submissions, and strategic partnerships shaping Cingulate's innovative pipeline. Our curated news collection includes updates on lead candidate CTx-1301's FDA review process, intellectual property expansions, and manufacturing advancements for PTR™-enabled therapies.
Key updates feature progress in addressing ADHD treatment limitations through single-dose efficacy solutions and developments in anxiety disorder management via novel drug delivery systems. All content undergoes rigorous verification to ensure alignment with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Cingulate's latest biopharmaceutical innovations, patent filings, and market expansion initiatives. Stay informed about critical developments in precision drug delivery technology without promotional bias or speculative content.
Cingulate Inc. announced that Peter J. Werth, a successful pharma entrepreneur and investor, will be featured with Chairman and CEO Shane J. Schaffer on a live Benzinga event. Werth will discuss his background and vision for Cingulate, while Schaffer will provide company updates. The event will take place on May 3, 2024, at 12:10 p.m. EST.
FAQ
What is the current stock price of Cingulate (CING)?
What is the market cap of Cingulate (CING)?
